National Lab Briefs

Getting Nobel Fever All Over Again A quarter-century ago, three Brookhaven National Lab physicists discovered the muon-neutrino, for which they were awarded this year’s Nobel Prize. Today plans are afoot to bring new glory to the aging accelerator that was the site of their research. The Department of Energy wants to use the 28-year-old machine, known as the Alternating Gradient Synchrotron, as an injector for a much larger proposed accelerator, the Relativistic Heavy Ion Collider. ̶

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A quarter-century ago, three Brookhaven National Lab physicists discovered the muon-neutrino, for which they were awarded this year’s Nobel Prize. Today plans are afoot to bring new glory to the aging accelerator that was the site of their research. The Department of Energy wants to use the 28-year-old machine, known as the Alternating Gradient Synchrotron, as an injector for a much larger proposed accelerator, the Relativistic Heavy Ion Collider. “The AGS has been extraordinarily fruitful, producing discoveries that have led to three different Nobel Prizes,” says Brookhaven physicist Thomas Ludlam. ‘We’re entering a similar era with RHIC,” which will collide heavy atomic nuclei in a search for free quarks. DOE has requested $275 million for RHIC in its 1990 budget to be submitted in January; if approved by Congress, construction could begin as soon as October 1989.

Dozens of foreign researchers found themselves locked out of U.S. national labs last ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies